



investigator
sponsored trials

fostering **INNOVATION**

NOVOCURE INVESTIGATOR SPONSORED TRIALS PROGRAM

Novocure supports independent, unsolicited research relating to Novocure approved and investigational products through its Investigator Sponsored Trials program in order to advance research and enhance disease understanding.

This program is open to physicians, researchers, and institutions interested in conducting their own research.

For more information on Investigator Sponsor Trial requests, please contact your local Medical Science Liaison, email us at ist@novocure.com, or visit <https://www.novocure.com/external-funding/>.

NEWLY DIAGNOSED GBM

A Prospective, Randomized, Single-Center Trial of NovoTTF-200A Together With Radiation Therapy and Temozolomide, Compared to Temozolomide and Radiation Therapy, Continued by Temozolomide and NovoTTF-200A in Patients With Newly Diagnosed GBM (N = 60)

Principal Investigator: Rachel Grossman, MD
🇮🇱 Tel-Aviv Sourasky Medical Center, Israel

ClinicalTrials.gov: NCT03869242
PCD: Mar 2021

Understanding the Patient and Clinician Characteristics That Influence the Decision of Pursuing TTFields Therapy (N = 40)

Principal Investigator: Priya Kumthekar-Bhasin, MD
Northwestern University, IL

PCD: Mar 2021

Retrospective Review of Patients Treated With TTFields at a Single-Center, With Correlative Genetic Data (N = 66)

Principal Investigator: Michael W. Ruff, MD
Mayo Clinic, MN

PCD: Jun 2021

PriCoTTF Trial: A Phase 1/2 Trial of TTFields (NovoTTF-200A) Prior and Concomitant to Radiotherapy in Newly Diagnosed Glioblastoma (N = 33)

Principal Investigator: Martin Glas, MD
🇩🇪 University of Essen Medical Center, Germany

German Clinical Trials Registry
DRKS-ID: DRKS00016667
PCD: Dec 2021

ACTION: A Longitudinal Observational Study of Quality of Life, Functional Capacity, and Physical Function in Glioblastoma Patients Treated With Tumor Treating Fields (NovoTTF-200A) (N = 36)

Principal Investigator: Katherine B. Peters, MD, PhD
The Preston Robert Tisch Brain Tumor Center, NC

ClinicalTrials.gov: NCT03501134
PCD: Sep 2022

Phase 2, Single-Arm, Historically Controlled Study Testing the Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (NovoTTF-200A) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) (N = 29)

Principal Investigator: David Tran, MD, PhD
University of Florida Health, FL

ClinicalTrials.gov: NCT03405792
PCD: Feb 2023

Phase 1 Study of Tumor Treating Fields (NovoTTF-200A) and a Personalized Mutation-Derived Tumor Vaccine in Patients With Newly Diagnosed Glioblastoma (N = 20)

Principal Investigator: Adilia Hormigo, MD, PhD
Icahn School of Medicine at Mount Sinai, NY

ClinicalTrials.gov: NCT03223103
PCD: May 2023

A Phase 1 Study of Tumor Treating Fields (NovoTTF-200A) with 5-Day Hypofractionated Stereotactic Radiosurgery and Concurrent and Maintenance Temozolomide in Newly Diagnosed Glioblastoma (N = 12)

Principal Investigator: Scott G. Soltys, MD
Stanford University, CA

ClinicalTrials.gov: NCT04474353
PCD: May 2023

The PROTECT Study: A Phase 2, Open-Label Trial of PROphylactic Skin Toxicity ThERapy With Clindamycin and Triamcinolone in Glioblastoma Patients Treated With Tumor Treating Fields (NovoTTF-200A) (N = 58)

Principal Investigator: Mario E. Lacouture, MD
Memorial Sloan Kettering Cancer Center, NY

ClinicalTrials.gov: NCT04469075
PCD: Jul 2023

RECURRENT GBM

▶ A Phase 2 Study of the Tumor Treating Fields (NovoTTF-100A) System, Enhanced by Genomic Analysis to Identify the Genetic Signature of Response in the Treatment of Recurrent Glioblastoma Multiforme (N = 26)

Principal Investigator: David Tran, MD, PhD
University of Florida Health, FL

ClinicalTrials.gov: NCT01954576
PCD: Sep 2021

▶ A Phase 2, Multicenter, Single-Arm, Historically Controlled Study Testing the Combination of TTFIELDS (NovoTTF-100A) and Pulsed Bevacizumab Treatment in Patients With Bevacizumab-Refractory Recurrent Glioblastoma (N = 18)

Principal Investigator: David Tran, MD, PhD
University of Florida Health, FL

ClinicalTrials.gov: NCT02663271
PCD: Mar 2022

▶ A Phase 2 Trial of Tumor Treating Fields (TTFIELDS, NovoTTF-200A) Concomitant With Radiosurgery for the Treatment of Recurrent, Bevacizumab-Naïve Glioblastoma (N = 40)

Principal Investigator: Maciej Harat, MD
 The Franciszek Lukaszczyk
Oncology Center, Poland

ClinicalTrials.gov: NCT04671459
PCD: Dec 2022

▶ Enhancing Tumor Treating Fields (NovoTTF-200A) for Recurrent Glioblastoma With Targeted and Individualized Skull-Remodeling Surgery: A Multicenter Randomized Phase 2 Trial (N = 70)

Principal Investigator: Anders Rosendal Korshøj, MD, PhD
 Aarhus University Hospital, Denmark

ClinicalTrials.gov: NCT04223999
PCD: Mar 2023

▶ A Phase 2 Study Evaluating the Efficacy and Safety of Niraparib and Tumor Treating Fields (NovoTTF-200A) in Recurrent Glioblastoma (N = 30)

Principal Investigator: Stephen Bagley, MD
Hospital of the University of Pennsylvania, PA

ClinicalTrials.gov: NCT04221503
PCD: Dec 2025

IMAGING

- Tryptophan Metabolism in Human Brain Tumors: For Patients Whose Clinical Treatment Includes NovoTTF (NovoTTF-200A) (N = 20)**
Principal Investigators: Csaba Juhász, MD, PhD, and Sandeep Mittal, MD
Wayne State University, MI
ClinicalTrials.gov: NCT02367482
PCD: Dec 2020
- Assessment of Tumor Treating Fields (NovoTTF-200A) Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI (N = 30)**
Principal Investigator: Jennifer Connelly, MD
Medical College of Wisconsin, WI
ClinicalTrials.gov: NCT03297125
PCD: May 2021
- High-Resolution MRI and MRS to Evaluate Therapeutic Response to Novo-TTF (NovoTTF-200A) in Newly Diagnosed and Recurrent Glioblastomas (N = 30)**
Principal Investigator: Suyash Mohan, MD
University of Pennsylvania, PA
ClinicalTrials.gov: NCT02441322
PCD: Dec 2021
- Development of Imaging Biomarkers for Monitoring and Prediction of Clinical Outcome After Tumor Treating Fields (NovoTTF-200A) Therapy (N = 10)**
Principal Investigators: Bogdan Draganski, MD, and Andreas Hottinger, MD, PhD
 The University Hospital of Vaud (CHUV), Lausanne, Switzerland

OTHER INDICATIONS OR TOPICS

CNS TUMORS

Feasibility Trial of Tumor Treating Fields (NovoTTF-200A) for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma (N = 25)

Principal Investigator: Stewart Goldman, MD
Pediatric Brain Tumor Consortium
Ann and Robert H. Lurie Children's Hospital of Chicago, IL
ClinicalTrials.gov: NCT03033992
PCD: Apr 2021

NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy (N = 20)

Principal Investigator: Peter LaViolette, PhD
Medical College of Wisconsin, WI
ClinicalTrials.gov: NCT03194971
PCD: May 2021

A Phase 2, Single-Arm, Multicenter, Open-Label Trial Combining Tumor Treating Fields (NovoTTF-200A) With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma (N = 27)

Principal Investigator: Priya Kumthekar, MD
Northwestern University, IL
ClinicalTrials.gov: NCT02847559
PCD: Sep 2021

Phase 2, Single Arm Study of NovoTTF-200A in Bevacizumab-Naïve Subjects With Recurrent WHO Grade III Malignant Astrocytoma (N = 26)

Principal Investigator: Daniela A. Bota, MD
University of California, Irvine, CA
ClinicalTrials.gov: NCT03450850
PCD: Jun 2023

A Phase 1 Trial of the Tumor Treating Fields NovoTTF-200A System in Combination With Temozolomide and Bevacizumab in Pediatric Patients With High-Grade Glioma and Ependymoma (N = 6)

Principal Investigator: Derek Hanson, MD
Hackensack University Medical Center, NJ
ClinicalTrials.gov: NCT03128047
PCD: Sep 2023

BRAIN METASTASES

Prophylactic Tumor Treating Fields (NovoTTF-200A) in Management of Patients With Small Cell Lung Cancer (N = 106)

Principal Investigator: Timur Mitin, MD, PhD
OHSU Knight Cancer Institute, OR
ClinicalTrials.gov: NCT03995667
PCD: Jun 2021

A Pilot and Feasibility Trial to Determine the Rate of the Brain Relapse in Small Cell Lung Cancer (SCLC) Patients With Brain Metastases Treated With Stereotactic Radiosurgery (SRS) Followed by Tumor Treating Fields (TTFields, NovoTTF-200A) (N = 20)

Principal Investigator: Drexell H. Boggs, MD
University of Alabama at Birmingham, AL
ClinicalTrials.gov: NCT03488472
PCD: Apr 2022

Phase 2 Study of TTFields (NovoTTF-200A) Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis (N = 23)

Principal Investigator: George Anstas, MD
Washington University School of Medicine, MO
ClinicalTrials.gov: NCT03903640
PCD: Jan 2024

Phase 1 and 2 Study of NovoTTF-200A and Pembrolizumab in Newly Diagnosed Melanoma Brain Metastasis (N = 30)

Principal Investigator: Eric T. Wong, MD
Beth Israel Deaconess Medical Center, MA
ClinicalTrials.gov: NCT04129515
PCD: May 2024

OTHER INDICATIONS OR TOPICS (CONTINUED)

GASTROINTESTINAL TUMORS

 A Phase 1 Study of the NovoTTF-100L(P) System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer (N = 52)

Principal Investigator: Siqing Fu, MD, PhD
MD Anderson Cancer Center, TX

ClinicalTrials.gov: NCT03203525
PCD: Dec 2021

